MedPath

Comparison the effect of vaginal Misoprostol and vaginal Isoniazid for cervical ripening prior to hysteroscopy procedures

Phase 2
Conditions
Abnormal uterine and vaginal bleeding, unspecified.
Abnormal uterine and vaginal bleeding, unspecified
Registration Number
IRCT2015112821506N4
Lead Sponsor
Iran University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
Female
Target Recruitment
100
Inclusion Criteria

postmenopausal women and premenopausal women who have no history of vaginal delivery, not pregnant at the time of examination, no contraindication for receiving prostaglandin , no severe vaginal prolapse , no previous surgery on cervix or cervical incompetence. Exclusion criteria: history of vaginal delivery, pregnancy, severe vaginal prolapse, previous surgery on cervix, history of cervical insufficiency, simultaneous laparoscopy and cervical myoma.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hysteroscopy entrance without cervical dilatation. Timepoint: During surgery. Method of measurement: Hagar size.
Secondary Outcome Measures
NameTimeMethod
The number and percent of patients needs for cervical dilatation. Timepoint: During surgery. Method of measurement: Counting.;Maximum Hagar size interring without forces. Timepoint: During surgery. Method of measurement: Hagar.
© Copyright 2025. All Rights Reserved by MedPath